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function and dysfunction of 
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Pathological modification of α-synuclein is believed to be an important event in pathogenesis of 
Parkinson’s disease and several other neurodegenerative diseases. In normal cells this protein has 
been linked to many intracellular processes and pathways. However, neither normal function of 
α-synuclein in neuronal and certain other types of cells nor its exact role in the disease pathogenesis 
is well understood, which is largely due to limitations of animal models used for studying this 
protein. We produced and validated several novel mouse lines for manipulating expression of the 
endogenous Snca gene coding for α-synuclein. These include a line for conditional Cre-recombinase-
driven inactivation of the gene; a line for conditional Flp-driven restoration of a neo-cassete-blocked 
α-synuclein expression; a new line with a “clean” constituent knockout of the gene as well as a 
line carrying this knockout locus and Rosa26-stop-lacZ reporter locus linked at the same mouse 
chromosome 6. Altogether these lines represent a set of new useful tools for studies of α-synuclein 
normal function and the role of this protein in disease pathogenesis.
Pathological aggregation of α -synuclein with formation of characteristic intracellular inclusions is a com-
mon feature of Parkinson’s disease (PD) and several neurodegenerative diseases, collectively known as 
synucleinopathies1–3. Moreover, certain structural modifications or increased expression of this protein 
have been associated with the development of early onset forms of PD4–9, whereas polymorphisms in the 
encoding locus, SNCA, have been found to affect the risk of the development of PD and certain other 
synucleinopathies10–14. Therefore, it is feasible that substantial changes in α -synuclein metabolism lead 
to the development of aggressive forms of the disease, while more subtle modifications can be efficiently 
compensated for a long time. Only later in life, probably in combination with certain environmental 
factors and/or with a general functional decline of the ageing nervous system, these subtle modifications 
trigger pathological changes and clinical manifestation of the disease.
A well-documented mechanism of α -synuclein-induced neuronal dysfunction and death is the tox-
icity of intermediate products of α -synuclein aggregation, namely oligomers and protofibrils (reviewed 
in15–18). However, this gain-of-function mechanism might be accompanied by a loss-of-function devel-
oping as the result of α -synuclein sequestering in aggregates and consequent depletion of the functional 
pool of this protein.
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α -synuclein is abundant in presynaptic terminals of many types of neurons where it might play an 
important role in neurotransmission via regulation of synthesis, release and re-uptake of various neuro-
transmitters19–30. Although α -synuclein deficiency in mouse models can be compensated for long time 
either due to the redundancy within the synuclein family or by switching on some other mechanism 
in the developing nervous system, ageing animals lacking α -synuclein develop neuronal and particu-
larly, synaptic deficiency31–34. Depletion of α -synuclein in adult rat substantia nigra by injection of 
siRNA-encoding AAV viruses caused a rapid development of substantially more severe neuronal dys-
function than observed in any of the previously produced animal lines with constituent inactivation of 
the Snca gene35. Another limitation of conventional α -synuclein knockout mouse models is that inactiva-
tion of the gene takes place in all body cells. Despite a particular abundance of α -synuclein in neurons, 
it is not possible to exclude a systemic effect of its depletion in other cells, e.g. erythrocytes, on animal 
physiology, which might hamper interpretation of the observed phenotypes. Therefore, the ability to 
targetedly and conditionally deplete specific cell population of α -synuclein is important for better under-
standing of this protein normal function and its role in human pathologies.
Having this in mind, we produce mice for conditional Cre-recombinase-driven inactivation of the 
Snca gene. In the process of producing and characterisation of these mice we created additional mouse 
lines, namely mice carrying inactivated Snca gene which expression can be conditionally restored by 
FLP-recombinase-driven deletion of the neo-cassette; “clean KO” mice, a novel line with constituent 
inactivation of Snca gene that carry neither neo-cassette nor other ectopic sequences that might interfere 
with the genome function; mice with the same “clean KO” linked with Rosa26-stop-lacZ reporter locus, 
which is located at the same mouse Chr 6.
Results and Discussion
Using traditional gene targeting approaches schematically illustrated in Fig. 1, we produced a novel line 
of mice than can be used for conditional inactivation of α -synuclein coding gene by Cre-driven recom-
bination within transcriptionally active Snca floxΔneo locus. The normal level of α -synuclein in the neural 
tissues of homozygous Snca floxΔneo/floxΔneo mice was confirmed by Western blot analysis (Fig. 2). To prove 
that deletion of the exon II by Cre recombination leads to complete inactivation of the gene we bred 
Snca floxΔneo/floxΔneo mice with an “early deletor” Cre mice (see Material and Methods) to achieve germline 
deletion of the floxed exon II and surrounding sequences. Homozygous SncaΔflox/Δflox mice were pro-
duced and Western blot analysis did not reveal any α -synuclein protein in neural tissues of these animals 
Figure 1. Gene targeting strategy for production of mice for conditional inactivation of α-synuclein 
gene and confirmation of introduced genomic modifications by Southern hybridisation. See 
Supplementary Fig. S1 for sequences of the wildtype (WT) and modified Snca loci.
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(Fig. 3). Therefore, successful Cre recombination within the engineered SncafloxΔneo/floxΔneo locus efficiently 
inactivates α -synuclein expression. The line of mice carrying Snca floxΔneo allele has been deposited to The 
Jackson Laboratory (C57BL/6-Snca< tm1.1 Vlb> /J; JAX Stock#025636). Breeding of these animals with 
various Cre transgenic mice or stereotaxic injection of Cre-expressing viral vectors shall make it possible 
to deplete specific cell population or brain areas of α -synuclein. By using tamoxifen-inducible Cre-ERT2 
transgenes this inactivation process can be initiated at any period of the animal development.
However, conditional inactivation of a gene in a selected cell population commonly requires a reporter 
for monitoring efficiency of Cre recombination. This is particularly important for α -synuclein that in 
most neurons is localised not in the perikarion of targeted neurons but in presynaptic terminals, which 
makes it difficult to confirm its selective and efficient depletion. Rosa26-stop-lacZ reporter36 is widely 
used for this purpose. However, in the mouse genome both Snca and Rosa26 loci are located at chro-
mosome 6 (Chr6) approximately 50 Mb apart. To make possible the use of Rosa26-stop-lacZ reporter in 
experiments with conditional inactivation of Snca gene we produced a mouse line carrying a completely 
inactivated SncaΔflox gene and Rosa26-stop-lacZ reporter linked at the same mouse Chr6 (see Materials 
and Methods). When control for the efficiency of Cre recombination is required, these mice and Snca 
floxΔneo mice could be used for production of an experimental cohort carrying an active floxed copy of 
Snca gene at one Chr6, and a constitutively inactive copy and Rosa26-stop-lacZ reporter on another 
Chr6. In addition to the possibility of monitoring the process of Cre recombination, the efficiency of the 
gene inactivation process is increased when such heterozygous animals are used, because to achieve a 
complete knockout in a given cell, only one allele needs to be inactivated. It should be noted that there 
is no evidence for any noticeable effects of Snca gene haploinsufficiency in mice.
Figure 2. Restoration of α-synuclein expression in the cerebral cortex of floxed mice following germline 
deletion of neo-cassette. Western blot analysis of total protein samples extracted from the cerebral cortex 
of wild type mice (SNCA+/+), α -synuclein knockout mice (SNCA−/−, described previously19), floxed 
mice before deletion of neo-cassette (SNCAflox(neo)/flox(neo)) and floxed mice after deletion of neo-cassette 
(SNCAfloxΔneo/floxΔneo).
Figure 3. Depletion of α-synuclein in the brain tissues of homozygous mice following germline Cre-
recombination. Western blot analysis of total protein samples extracted from the cerebral cortex (Cx) 
and midbrain (Mb) of a homozygous (SNCAfloxΔneo/floxΔneo) α -synuclein floxed mouse after deletion of 
the neo-cassette and two homozygous α -synuclein floxed mice after deletion of the exon II by Cre/loxP 
recombination (SNCAΔflox/Δflox).
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The line of mice with constituent inactivation of Snca gene (SncaΔflox/Δflox) has a value of its own 
because for the best of our knowledge, it represents the most “clean” full α -synuclein knockout pro-
duced so far. Other published mouse lines still carry various selection cassettes in the vicinity of the 
inactivated Snca gene19,20,37,38 and the natural mutant line from Harlan UK39 possesses a deletion of 
approximately 350 kb fragment that includes Snca along with other genes. In contrast, the only ectopic 
sequence remained in the new SncaΔflox/Δflox line is a single loxP site and the deletion is restricted to the 
1164 bp fragment containing exon II and adjacent intronic sequences of the Snca gene. The importance 
of using animals with less invasive genetic manipulations for accurate revealing the effects of α -synuclein 
depletion can be illustrated by the fact that in a widely used mouse knockout line19 the level of neu-
ronal expression of the Mmrn1 gene (encoding multimerin 1) located close to the modified Snca gene is 
increased when compared to wild type or our SncaΔflox/Δflox mice (our unpublished observations), while 
in the Harlan UK mutant line this gene is completely absent. In both cases potential effects of these 
expression changes on neuronal physiology can be erroneously attributed to the absence of α -synuclein.
Analysis of α -synuclein expression in the nervous system of homozygous Sncaflox(neo)/flox(neo) mice 
generated at the first step of the targeting programme (see Fig.  1) revealed that the presence of the 
neo-cassette in the gene intron completely abolished α -synuclein production (Fig. 2). However, conse-
quent Flp-driven deletion of this cassette restored normal expression of the protein in SncafloxΔneo/floxΔneo  
mice (Fig.  2). Therefore, Sncaflox(neo)/flox(neo) line can be used for conditional switching on endogenous 
α -synuclein expression in specific cell populations and/or developmental periods. This might be achieved 
by breeding mice of this line with transgenic mice expressing Flp recombinase under control of specitic 
promoters or by using stereotaxic injections of Flp expressing viral vectors.
In summary, we have produced a set of unique mouse lines for conditional switching off or switching 
on expression of endogenous α -synuclein as well as a novel improved line with constituent inactivation 
of the α -synuclein encoding gene. These lines represent new useful tools for studies of the normal func-
tion of α -synuclein in selected populations of neuronal and non-neuronal cells as well as the role of this 
protein in the development of neurodegenerative processes and transmission of α -synuclein pathology 
through the nervous system.
Materials and Methods
Targeting construct. To create arms for homologous recombination (for sequences see Supplementary 
Materials and Methods), fragments from the region of the exon II of mouse Snca gene (encoding amino 
acids 1–41 of α -synuclein) were PCR amplified using DNA extracted from C57Bl6-derived ES cells (line 
JM8A3.N1, gift of Dr. William Skarnes, Sanger Institute, Cambridge, UK) as a template. A high fidelity 
AccuPrime Pfx SuperMix (Invitrogen) and primers carrying desired additional sequences (loxP, FRT 
and/or restriction endonuclease cleavage sites) were used. PCR fragments were then cloned into the pCR-
Blunt II-TOPO vector (Invitrogen) and verified by sequencing. Following digestion with appropriate 
restriction endonucleases, resulting engineered DNA fragments were cloned into pPNT1 vector plasmid 
to produce final targeting construct schematically shown in Fig. 1.
Gene targeting in mouse ES cells and generation of mouse founders. Mouse ES JM8A3.N1 
cells40 were electroporated with the NotI-linearised targeting plasmid followed by selection of G418 and 
gancyclovir resistant clones. DNA extracted from individual clones was analysed for homologous recom-
bination by Southern hybridisation with two outside probes (for sequences see Supplementary Fig. S1) 
as shown in Fig. 1. DNA extraction, Southern blotting, 32P-labeling of probes, hybridisation and washes 
were carried out according to protocols described previously41. Positive clones were expanded and used 
for injection into blastocysts of C57Bl6 cells followed by the embryotransfer into the uterus of pseudo-
pregnant CD1 mice. Resulting chimeras were bred with C57Bl6 mice and successful germline transfer of 
the modified locus was confirmed by PCR analysis of DNA from ear biopsies.
Production of experimental mouse lines. Mice carrying a targeted α -synuclein locus (Snca flox(neo)/+) 
were backcrossed with C57BL/6 mice for five generations and then intercrossed to produce animals 
homozygous for this locus (Snca flox(neo)/ flox(neo)) and wild type littermates (Snca+/+).
To remove the neo-cassette, mice carrying a targeted α -synuclein locus were bred to C57BL/6 mice 
for two generations and then crossed to transgenic mice expressing FLP recombinase under control 
of beta-actin promoter (B6.Cg-Tg(ACTFLPe)9205Dym/H, on the C57BL/6 genetic background, The 
Jackson Laboratory). Successful deletion of FRT-flanked neo-cassette was confirmed by Southern hybrid-
isation and PCR analysis of DNA from ear biopsies.
Mice with deleted neo-cassette (Snca floxΔneo/+) were further bred to C57BL/6 J mice and selection 
was applied to remove the FLP recombinase transgene. Homozygous (Snca floxΔneo/floxΔneo) and wild type 
littermates were produced by the intercrossing of mice that went through seven generations of the 
backcrossing.
To produce mice with constituent inactivation of α -synuclein gene Snca floxΔneo/floxΔneo mice were 
crossed with transgenic mice (on C57Bl6 background) expressing Cre recombinase under control of 
CMV promoter42. Mice with deleted neo-cassette (Snca Δflox/+) were further backcrossed to C57BL/6J 
mice and those lacking the Cre recombinase transgene were selected. Intercrosses of these mice produced 
homozygous (Snca Δflox/Δflox) animals.
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Mice carrying Snca Δflox and Rosa26-stop-lacZ reporter36 loci linked at the same chromosome as the 
result of natural crossover were selected from a pool of animals generated during crossbreeding of two 
mouse lines (both on C57Bl6 background), each bearing one of these modified loci.
Animal genotyping. Animal genotypes were verified by PCR analysis of DNA from ear biopsies 
using combinations of primers and amplification conditions described in Supplementary Materials and 
Methods.
Western blotting. Total protein samples were prepared by homogenisation of mouse tissues in 
the SDS-PAGE loading buffer following incubation for 10 min at 100 oC. Gel electrophoresis, trans-
fer to PVDF membrane, incubation with primary and secondary HRT-conjugated antibodies, and 
chemiluminescent-based detection were performed as described previously32. For detection of α -synuclein 
mouse monoclonal antibody (BD 610786 from BD Biosciences) were used in 1:1000 dilution. To confirm 
the equal loading membranes were re-probed with mouse monoclonal anti-beta-actin antibody (AC-15 
from Sigma-Aldrich) in 1:10000 dilution.
All animal work was carried out in accordance with the United Kingdom (Scientific Procedures) 
Act (1986) and European Directive EC 86/609, and has been approved by the Cardiff University Ethical 
Review Committee and the Home Office (Project Licence 30/2844).
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